MOSCOW (Reuters) – A one-dose course of Russia’s Sputnik vaccine against COVID-19 will have an efficacy rate of 73-85%, the head of the country’s sovereign wealth fund told Reuters on Thursday.
Authorities said on Monday that Russia would conduct a clinical trial of a one-dose version of its coronavirus vaccine, describing it as a possible “temporary” solution to help countries with high infection rates make the drug go further.
(Reporting by Andrew Osborn and Polina Ivanova; writing by Tom Balmforth; editing by John Stonestreet)
